An interventional study of Eldith Company - direct current stimulator and Eldith Company - direct current stimulator in Major Depression, sponsored by The University of New South Wales. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2023-03-30.
Sponsored by The University of New South Wales · Not applicable, Interventional, and Treatment
Among antidepressant treatments, ECT stands as the most effective in treating acute depression. However, patient concerns with the cognitive side effects of ECT have encouraged the development of new and more focal forms of brain stimulation such as transcranial Direct Current Stimulation (tDCS). However, not all patients may respond to this treatment in the way that it is currently administered and this has raised interest in finding alternative, possibly more optimal ways of administering tDCS. This study will investigate whether tDCS stimulation using an alternative electrode montage has antidepressant effects. Further sessions of tDCS, spaced less frequently, will be trialed for maintenance treatment. Mood, cognitive test performance and biomarkers will be measured periodically in the duration of the trial.
8,057 studies on the registry are indexed under Depression; 1,641 are open to participants now.
This study's enrollment of 24 is below the median of 84 across 6,720 interventional studies indexed under Depression.
Browse Depression studies →The University of New South Wales is the lead sponsor of 65 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Device: Eldith Company - direct current stimulator
Device: Eldith Company - direct current stimulator
Direct current stimulation montage 1.
Also known as: Neuroconn - direct current stimulator
Direct current stimulation montage 2.
Also known as: Neuroconn - direct current stimulator
Montgomery Asberg Depression Rating Scale for Depression (MADRS).
Time frame: 4 weeks
This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The University of New South Wales